Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* On statin treatment for at least 3 months (fluvastatin, simvastatin, pravastatin, rosuvastatin, or atorvastatin) for primary prevention of cardiovascular disease~* HIV Ribonucleic Acid (RNA) below 50 copies/mL, minimum duration 3 months~* On a stable (\> 3 months) ARV treatment including at least one of the following drugs: LPV/r, ATZ/r, DRV/r, or EFV~* No previous virological escape or virological escape documented with a genotype at the time of failure only showing a K103M mutation.~Exclusion Criteria:~* Probability of cardiovascular complications of \> 20% according to the Swiss GSLA (Groupe de travail Lipide et Athérosclérose/Swiss Atherosclerosis Association) guidelines~* Previous cardiovascular disease (including stroke)~* Known diabetes~* Known intolerance of ETR~* Presence of a documented drug mutation (excluding the K103M)~* Regimen including non-boosted ATZ~* Known hyperlipidemia before ARV initiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Etravirine switch (Type: EXPERIMENTAL): Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine

Based on this trial design, predict the completion outcome and termination type (if applicable).